BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles
نویسندگان
چکیده
OBJECTIVE To provide a framework for addressing payers' criteria during the development of pharmaceuticals. METHODS A conceptual framework was presented to an international health economic expert panel for discussion. A structured literature search (from 2010 to May 2015), using the following databases in Ovid: Medline(®) and Medline(®) In-Process (PubMed), Embase (Ovid), EconLit (EBSCOhost) and the National Health Service Economic Evaluation Database (NHS EED), and a 'grey literature' search, were conducted to identify existing criteria from the payer perspective. The criteria assessed by existing frameworks and guidelines were collated; the most commonly reported criteria were considered for inclusion in the framework. A mnemonic was conceived as a memory aide to summarise these criteria. RESULTS Overall, 41 publications were identified as potentially relevant to the objective. Following further screening, 26 were excluded upon full-text review on the basis of no framework presented (n = 13), redundancy (n = 11) or abstract only (n = 2). Frameworks that captured criteria developed for or utilised by the pharmaceutical industry (n = 5) and reimbursement guidance (n = 10) were reviewed. The most commonly identified criteria-unmet need/patient burden, safety, efficacy, quality-of-life outcomes, environment, evidence quality, budget impact and comparator-were incorporated into the summary framework. For ease of communication, the following mnemonic was developed: BEACON (Burden/target population, Environment, Affordability/value, Comparator, Outcomes, Number of studies/quality of evidence). CONCLUSIONS The BEACON framework aims to capture the 'essence' of payer requirements by addressing the most commonly described criteria requested by payers regarding the introduction of a new pharmaceutical.
منابع مشابه
Selecting the acceptance criteria of medicines in the reimbursement list of public health insurance of Iran, using the “Borda”method: a pilot study
Decision-making for medicines to be accepted in Iran’s public health insurance reimbursement list is a complex process and involves factors, which should be considered in applying a coverage for medicine costs. These processes and factors are not wholly assessed, while assessment of these factors is an essential need for getting a transparent and evidence-based approach toward medicine reimburs...
متن کاملSelecting the acceptance criteria of medicines in the reimbursement list of public health insurance of Iran, using the “Borda”method: a pilot study
Decision-making for medicines to be accepted in Iran’s public health insurance reimbursement list is a complex process and involves factors, which should be considered in applying a coverage for medicine costs. These processes and factors are not wholly assessed, while assessment of these factors is an essential need for getting a transparent and evidence-based approach toward medicine reimburs...
متن کاملTypical Ka band Satellite Beacon Receiver Design for Propagation Experimentation
This paper presents the design and simulation of a typical Ka band satellite beacon receiver for propagation experimentation. Using satellite beacon signal as a reference signal in satellite wave propagation study, is one of the most important methods. Satellite beacons are frequently available for pointing large antennas, but such signals can be used for measuring the effect of natural phenome...
متن کاملPredictive coding and the Bayesian brain: Intractability hurdles that are yet to be overcome
Introduction An influential conjecture in neuroscience states that a brain organized according to principles of hierarchical predictive coding (HPC) can effectively and efficiently perform genuine Bayesian inferences, providing a neurally plausible account of how Bayesian models of cogntion may be physically implemented in the brain. However, each key subcomputation invoked in HPC potentially h...
متن کاملStratified Medicine and Reimbursement Issues
Stratified Medicine (SM) has the potential to target patient populations who will most benefit from a therapy while reducing unnecessary health interventions associated with side effects. The link between clinical biomarkers/diagnostics and therapies provides new opportunities for value creation to strengthen the value proposition to pricing and reimbursement (P&R) authorities. However, the int...
متن کامل